

## **Notice to holders of the ABSA warrants issued on April 7, 2025 by DBV Technologies (the "Company") (ISIN code: FR001400TXA1) (the "ABSA Warrants")**

*Capitalized terms not otherwise defined in this notice shall have the meaning given to them in the terms and conditions of the ABSA Warrants (the "Terms and Conditions").*

Pursuant to Conditions 2.(a) and 13 of the Terms and Conditions, Holders are hereby notified that the VITESSE Positive Results referred in the Terms and Conditions occurred today (as disclosed in the press release published on December 16, 2025 – [<https://dbv-technologies.com/investor-overview/news/>]).

In connection with this announcement, the Company reminds the Holders that the ABSA Warrants are now exercisable until 30 days following the publication of the above-mentioned press release by the Company, i.e., January 15, 2026.

For further information, please refer to the Terms and Conditions.

\* \* \*

### **About DBV Technologies**

DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of VIASKIN® Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

VIASKIN is a registered trademark of DBV Technologies.